Community Optometrist–Led Monitoring of Quiescent Neovascular Age-Related Macular Degeneration: The FENETRE - Takeaways - MDSpire

Community Optometrist–Led Monitoring of Quiescent Neovascular Age-Related Macular Degeneration: The FENETRE

  • By

  • Anitta Sharma

  • Aljazy Jaber

  • Bishwanath Pal

  • John G. Lawrenson

  • Robert A. Harper

  • Adnan Tufail

  • Annastazia E. Learoyd

  • Emily Robinson

  • Abdel Douiri

  • Rachel Burman

  • Ashleigh Kernohan

  • Sofia Vougioukalou

  • Simon Read

  • Judit Csontos

  • Aled Jones

  • Sajjad Mahmood

  • Martin McKibbin

  • Janet L. Peacock

  • Richard Gale

  • Praveen J. Patel

  • Pearse A. Keane

  • Robin Hamilton

  • Luke Vale

  • Catey Bunce

  • Konstantinos Balaskas

  • June 15, 2026

  • 0 min

Share

  • 1

    The FENETRE trial evaluates community optometrist monitoring for stable neovascular age-related macular degeneration (nAMD) compared to hospital-based monitoring.

  • 2

    Participants aged 55 and older with quiescent nAMD were randomized to either community optometry practices or hospital clinics for monitoring over 12 months.

  • 3

    Community optometrists received dedicated training and accreditation to ensure effective monitoring of nAMD and potential reactivation.

  • 4

    The study aims to determine if community-based monitoring is noninferior to hospital monitoring in detecting nAMD reactivation or new cases.

  • 5

    Outcome assessment involved comparing results against a central reading center, ensuring rigorous evaluation of monitoring effectiveness.

Original Source(s)

Community Optometrist–Led Monitoring of Quiescent Neovascular Age-Related Macular Degeneration: The FENETRE

  • by Anitta Sharma, Aljazy Jaber, Bishwanath Pal, John G. Lawrenson, Robert A. Harper, Adnan Tufail, Annastazia E. Learoyd, Emily Robinson, Abdel Douiri, Rachel Burman, Ashleigh Kernohan, Sofia Vougioukalou, Simon Read, Judit Csontos, Aled Jones, Sajjad Mahmood, Martin McKibbin, Janet L. Peacock, Richard Gale, Praveen J. Patel, Pearse A. Keane, Robin Hamilton, Luke Vale, Catey Bunce, Konstantinos Balaskas

  • June 15, 2026

Related Content

Mapping the FLIGHT Path

How incision-free intervention could expand glaucoma treatment options

Precision treatment of chalazion based on AI-driven risk stratification: a prospective study of triamcinolone acetonide combined with intense pulsed light therapy

Assessment of the aggregate index of systemic inflammation in dyslipidemia with dry eye disease: a retrospective case-control